(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-1.00%) $81.11
(-2.26%) $1.946
(-0.19%) $2 298.60
(0.17%) $26.70
(-0.43%) $944.10
(0.13%) $0.938
(0.29%) $11.13
(0.11%) $0.801
(0.00%) $93.45
-0.12% ¥ 8 580.00
Live Chart Being Loaded With Signals
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally...
Stats | |
---|---|
Volumen de hoy | 966 000 |
Volumen promedio | 0.00 |
Capitalización de mercado | 703.28B |
EPS | ¥0 ( 2024-02-12 ) |
Próxima fecha de ganancias | ( ¥-12.48 ) 2024-05-08 |
Last Dividend | ¥50.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 83.43 |
ATR14 | ¥533 134 202 (0.23%) |
Volumen Correlación
Taisho Pharmaceutical Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Taisho Pharmaceutical Correlación - Moneda/Commodity
Taisho Pharmaceutical Finanzas
Annual | 2022 |
Ingresos: | ¥301.38B |
Beneficio Bruto: | ¥177.85B (59.01 %) |
EPS: | ¥231.72 |
FY | 2022 |
Ingresos: | ¥301.38B |
Beneficio Bruto: | ¥177.85B (59.01 %) |
EPS: | ¥231.72 |
FY | 2022 |
Ingresos: | ¥268.20B |
Beneficio Bruto: | ¥163.83B (61.09 %) |
EPS: | ¥161.12 |
FY | 2021 |
Ingresos: | ¥282.04B |
Beneficio Bruto: | ¥175.99B (62.40 %) |
EPS: | ¥166.84 |
Financial Reports:
No articles found.
Taisho Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥50.00 (N/A) |
¥0 (N/A) |
¥50.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥50.00 | 2010-03-29 |
Last Dividend | ¥50.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 27 | -- |
Total Paid Out | ¥1 320.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.76 | -- |
Div. Sustainability Score | 7.14 | |
Div.Growth Potential Score | 2.76 | |
Div. Directional Score | 4.95 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6638.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
5965.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
4662.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
3902.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
3134.T | Ex Dividend Junior | 2024-04-26 | Annually | 0 | 0.00% | |
2004.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8999.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8550.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7872.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7013.T | No Dividend Player | 2023-09-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0263 | 1.500 | 9.47 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00838 | 1.200 | 9.72 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0104 | 1.500 | -0.996 | -1.494 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.16 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.19 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.04 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 87.55 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.572 | 1.000 | 3.80 | 3.80 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0590 | 1.000 | -0.819 | -0.819 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.319 | 0.800 | -1.209 | -0.967 | [0.5 - 2] |
Total Score | 7.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 83.52 | 1.000 | 1.665 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0104 | 2.50 | -0.640 | -1.494 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.166 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -24.40 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.197 | 1.000 | 7.58 | 0 | [0.1 - 0.5] |
Total Score | 2.76 |
Taisho Pharmaceutical
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico